STIMEP : Assessment of Subthalamic Nucleus Stimulation in Drug Resistant Epilepsy

Epilepsy Clinical Trial

Official title:

Assessment of Subthalamic Nucleus Stimulation in Drug Resistant Epilepsy Associated With Dopaminergic Metabolism Deficit. A Randomized, Double Blind, Controlled Trial.

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00228371
• Other study ID #: DCIC 03 23
• Status: Terminated
• Phase: Phase 2/Phase 3
• First received: September 26, 2005
• Last updated: May 27, 2015
• Start date: September 2005
• Est. completion date: March 2010

Study information

• Verified date: May 2015
• Source: University Hospital, Grenoble
• Contact: n/a
• Is FDA regulated: No
• Health authority: France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
• Study type: Interventional

Clinical Trial Summary

The aim of this study is to evaluate the effectiveness and the safety of deep brain stimulation in drug resistant epilepsy.

This is a double blind, controlled and randomized clinical trial with two cross-over groups and four phases.

Phase 1 : base line, open phase consisting of follow-up of patients with their standard treatment.

Phase 2 : Randomisation, lead implantation, followed by 3 months wash out period with the stimulator switch OFF.

Phase 3 : cross-over, double blind phase : 3 months with stimulator switch ON or OFF depending on randomization allocation, followed by 3 months with the stimulator switch on the opposite position. The placebo consisting of turn OFF the stimulator.

Phase 4 : open phase, one year follow-up of all patients with the stimulator switch ON.

Description:

The experimental work performed for more than 15 years by several research teams shows in animal models of epilepsy, that several circuits of basal ganglia are involved in the control of epilepsy seizures. The existence of those circuits leads to the possibility of therapeutic applications in particular deep brain stimulation.

Preliminary results (Benabid et al, 2002) (Chabardes et al , 2002) suggest that the neuromodulation of basal ganglia and in particular the subthalamic nucleus and the substantia nigra pars reticulata could have a therapeutic effects in patients with drug resistant epilepsy and no possibility of resection surgery.

This is a double blind, controlled and randomized clinical trial with two cross-over groups and four phases.

Phase 1 : base line, open phase consisting of follow-up of patients with their standard treatment.

Phase 2 : Randomisation, lead implantation, followed by 3 months wash out period with the stimulator switch OFF.

Phase 3 : cross-over, double blind phase : 3 months with stimulator switch ON or OFF depending on randomization allocation, followed by 3 months with the stimulator switch on the opposite position.

Phase 4 : open phase, one year follow-up of all patients with the stimulator switch ON.

There are two differents groups at phase 3 :

• Group A : 10 patients with the stimulator switch ON for three months and switch OFF for the next three months.

• Group B : 10 patients with the opposite sequence, OFF and ON.

Main objective :

• To show that high frequency deep brain stimulation of the subthalamic nucleus decrease the frequency of epileptic seizure compared with no stimulation.

Secondary objectives :

• To show that high frequency deep brain stimulation of the subthalamic nucleus improve the quality of life.

• To describe the side effects of this device and compare with those described in Parkinson patients. In particular to check the onset of dyskinesia related to dopamine.

• To compare the distribution of seizure frequency after stimulation to the base line.

• To show that the number of patients responding to treatment are higher in the group with stimulator switch ON than in the group with the stimulator turn OFF.

• To compare the number of days without seizure with the stimulator switch ON or OFF.

• To evaluated the neuropsychologic effect induced by the neurostimulation

• To quantify the types and the ratio of different seizures during the ON phase and the OFF phase.

• To monitor the secondary drug use during the study.

Control visits : all patients will have a control visit every 4 weeks during the study.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 4
• Est. completion date: March 2010
• Est. primary completion date: December 2009
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 50 Years

Eligibility

Inclusion Criteria:

• Epilepsy resistant to antiepileptic drug and dopaminergic D2 agonist.

• No curative exeresis surgery possible

• Metabolism deficiency of DOPA above 1 DS, evaluated by Positron Emission Tomography (PET) using fluorodopa

• Age ranging from 18 to 50

• capacity to consent

• Affiliation to the French Social Security

Exclusion Criteria:

• pregnant woman or nursing mother

• change of antiepileptic, 30 days before base line

• convulsive "etat de mal" that requires an hospitalisation, 30 days before base line

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Drug Resistant
• Epilepsy

Intervention

Device:
• Neurostimulation
High frequency neurostimulation of subthalamic nucleus : quadrupolar electrode, type 3389, n° : I7 02 08 39709 158, Medtronic, Minneapolis, USA

Locations

Country	Name	City	State
France	University Hospital of Grenoble	Grenoble	Isere
France	University Hospital of Rennes	Rennes
France	University Hospital of Strasbourg	Strasbourg

Sponsors (2)

Lead Sponsor	Collaborator
University Hospital, Grenoble	Ministry of Health, France

Country where clinical trial is conducted

France, 

References & Publications (9)

Alexander GE, Crutcher MD. Functional architecture of basal ganglia circuits: neural substrates of parallel processing. Trends Neurosci. 1990 Jul;13(7):266-71. Review. — View Citation

Ardouin C, Pillon B, Peiffer E, Bejjani P, Limousin P, Damier P, Arnulf I, Benabid AL, Agid Y, Pollak P. Bilateral subthalamic or pallidal stimulation for Parkinson's disease affects neither memory nor executive functions: a consecutive series of 62 patients. Ann Neurol. 1999 Aug;46(2):217-23. — View Citation

Benabid AL, Koudsie A, Benazzouz A, Vercueil L, Fraix V, Chabardes S, Lebas JF, Pollak P. Deep brain stimulation of the corpus luysi (subthalamic nucleus) and other targets in Parkinson's disease. Extension to new indications such as dystonia and epilepsy. J Neurol. 2001 Sep;248 Suppl 3:III37-47. Review. — View Citation

Benabid AL, Minotti L, Koudsié A, de Saint Martin A, Hirsch E. Antiepileptic effect of high-frequency stimulation of the subthalamic nucleus (corpus luysi) in a case of medically intractable epilepsy caused by focal dysplasia: a 30-month follow-up: technical case report. Neurosurgery. 2002 Jun;50(6):1385-91; discussion 1391-2. — View Citation

Chabardès S, Kahane P, Minotti L, Koudsie A, Hirsch E, Benabid AL. Deep brain stimulation in epilepsy with particular reference to the subthalamic nucleus. Epileptic Disord. 2002 Dec;4 Suppl 3:S83-93. — View Citation

Chkhenkeli SA, Chkhenkeli IS. Effects of therapeutic stimulation of nucleus caudatus on epileptic electrical activity of brain in patients with intractable epilepsy. Stereotact Funct Neurosurg. 1997;69(1-4 Pt 2):221-4. — View Citation

Cooper IS, Amin I, Gilman S. The effect of chronic cerebellar stimulation upon epilepsy in man. Trans Am Neurol Assoc. 1973;98:192-6. — View Citation

DeLong MR. Primate models of movement disorders of basal ganglia origin. Trends Neurosci. 1990 Jul;13(7):281-5. Review. — View Citation

Dematteis M, Kahane P, Vercueil L, Depaulis A. MRI evidence for the involvement of basal ganglia in epileptic seizures: an hypothesis. Epileptic Disord. 2003 Sep;5(3):161-4. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	- Daily seizure frequency at each phase		at each phase	Yes
Secondary	The number of days without seizure during each phase		at each phase	Yes
Secondary	Quality of life : SEALS, QOLIE-31 and NHP scales		at each phase	Yes
Secondary	Neuropsychological test : WAIS, GROBER and Busckhe, Wisconsin Card Sorting Test, TRAIL test, LURIA test, Beck Depression Inventory, verbal flow test, empathy test		at each phase	Yes